Sex hormones play key roles in both embryological development and adult tissue homeostasis. In this scenario, several studies demonstrated that dysregulation of sex hormone-related cell signaling is involved in both the occurrence and progression of human cancers. In particular, the estrogen-progesterone axis is one of the most important signaling involved in the breast, ovarian, lung and prostate diseases. In light of this, the expression of estrogen and/or progesterone receptor is considered a prognostic and predictive biomarker of breast cancer. In fact, high expression of the estrogen receptor is a predictor of the response of anti-estrogenic therapy. Although drugs targeting sex hormone functions are useful in treating cancer, tumors often develop resistance. Therefore, a better understanding of the downstream effectors of sex hormones is needed to develop new treatment strategies for these cancers. Also, the involvement of sex hormone, especially estrogen and progesterone, in human cancer development open an important question about the possible association among the intake of oral contraceptive and the risk of breast and ovarian cancer occurrence.
Starting from these considerations, the aim of this Research Topic is to publish the latest discoveries and bring together researchers and clinicians working in the field of “Estrogen and Progesterone Axis in Human Cancers”. We welcome submissions of Original Research articles and Reviews focusing on but not limited to:
1) Biological effects of estrogen and progesterone and their receptors in human cancers.
2) Novel aspects of estrogen and progesterone signaling in tumor cells as well as other cell types within the tumor microenvironment.
3) Hormonal therapies for cancer treatment and prevention, including novel agents or combination treatment modalities and resistance mechanisms.
4) Hormone receptors as predictive biomarkers in human cancers.
5) Estrogen and progesterone receptors genotypes.
6) Role of oral contraceptive use in dysregulation of estrogen-progesterone axis.
7) Cancer risk associated with oral contraceptive intake or hormone replacement therapy.
Sex hormones play key roles in both embryological development and adult tissue homeostasis. In this scenario, several studies demonstrated that dysregulation of sex hormone-related cell signaling is involved in both the occurrence and progression of human cancers. In particular, the estrogen-progesterone axis is one of the most important signaling involved in the breast, ovarian, lung and prostate diseases. In light of this, the expression of estrogen and/or progesterone receptor is considered a prognostic and predictive biomarker of breast cancer. In fact, high expression of the estrogen receptor is a predictor of the response of anti-estrogenic therapy. Although drugs targeting sex hormone functions are useful in treating cancer, tumors often develop resistance. Therefore, a better understanding of the downstream effectors of sex hormones is needed to develop new treatment strategies for these cancers. Also, the involvement of sex hormone, especially estrogen and progesterone, in human cancer development open an important question about the possible association among the intake of oral contraceptive and the risk of breast and ovarian cancer occurrence.
Starting from these considerations, the aim of this Research Topic is to publish the latest discoveries and bring together researchers and clinicians working in the field of “Estrogen and Progesterone Axis in Human Cancers”. We welcome submissions of Original Research articles and Reviews focusing on but not limited to:
1) Biological effects of estrogen and progesterone and their receptors in human cancers.
2) Novel aspects of estrogen and progesterone signaling in tumor cells as well as other cell types within the tumor microenvironment.
3) Hormonal therapies for cancer treatment and prevention, including novel agents or combination treatment modalities and resistance mechanisms.
4) Hormone receptors as predictive biomarkers in human cancers.
5) Estrogen and progesterone receptors genotypes.
6) Role of oral contraceptive use in dysregulation of estrogen-progesterone axis.
7) Cancer risk associated with oral contraceptive intake or hormone replacement therapy.
